1. In vitro assessment of novel transcription inhibitors and topoisomerase poisons in rhabdomyosarcoma cell lines

   • Steven J. Wolf
   • Laurence P. G. Wakelin
   • Daniel R. Catchpoole

   Original Article 10 March 2009 Pages: 1059 - 1069

   

2. A phase I study of palliative chemoradiation therapy with paclitaxel and cisplatin for local symptoms due to an unresectable primary advanced or locally recurrent gastric adenocarcinoma

   • Takaki Yoshikawa
   • Akira Tsuburaya
   • Junichi Sakamoto

   Original Article 13 March 2009 Pages: 1071 - 1077

   

3. Preliminary results of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced or metastatic transitional cell carcinoma of the urothelium

   • Yoshiaki Yamada
   • Youko Itoh
   • Nobuaki Honda

   Original Article 11 March 2009 Pages: 1079 - 1083

   

4. Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy

   • Alain G. Musende
   • Andy Eberding
   • Emma Tomlinson Guns

   Original Article 20 March 2009 Pages: 1085 - 1095

   

5. Panaxadiol, a purified ginseng component, enhances the anti-cancer effects of 5-fluorouracil in human colorectal cancer cells

   • Xiao-Li Li
   • Chong-Zhi Wang
   • Chun-Su Yuan

   Original Article 11 March 2009 Pages: 1097 - 1104

   

6. Endurance exercise training preserves cardiac function in rats receiving doxorubicin and the HER-2 inhibitor GW2974

   • Karen Y. Wonders
   • David S. Hydock
   • Reid Hayward

   Original Article 08 April 2009 Pages: 1105 - 1113

   

7. Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells

   • Maiko Suzuki
   • Manabu Endo
   • Hidemi Rikiishi

   Original Article 11 March 2009 Pages: 1115 - 1122

   

8. Erlotinib in advanced non-small-cell lung cancer after gefitinib failure

   • Zheng-Tao Zhou
   • Xin-Hua Xu
   • Cai-Hong Wen

   Original Article 26 March 2009 Pages: 1123 - 1127

   

9. Schedule-dependent synergism and antagonism between pemetrexed and docetaxel in human lung cancer cell lines in vitro

   • Yasuhiko Kano
   • Masaru Tanaka
   • Yusuke Furukawa

   Original Article 22 March 2009 Pages: 1129 - 1137

   

10. A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer

    • Olivier Rixe
    • Sandra X. Franco
    • Hope S. Rugo

    Original Article 18 March 2009 Pages: 1139 - 1148

    

11. Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study

    • Stephen I. Shibata
    • James H. Doroshow
    • Edward M. Newman

    Original Article 26 March 2009 Pages: 1149 - 1155

    

12. Antineoplastic activity of idazoxan hydrochloride

    • G. F. Eilon
    • L. Weisenthal
    • L. M. Slater

    Original Article Open access 24 March 2009 Pages: 1157 - 1163

    

13. Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors

    • Noboru Yamamoto
    • Tomohide Tamura
    • Eisei Shin

    Original Article 24 March 2009 Pages: 1165 - 1172

    

14. Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer

    • Hui-Ju Ch’ang
    • Chin-Lun Huang
    • Li-Tzong Chen

    Original Article 25 March 2009 Pages: 1173 - 1179

    

15. A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer

    • Yoshitaka Totani
    • Yuji Saito
    • Hiroki Sakakibara

    Original Article 18 April 2009 Pages: 1181 - 1185

    

16. Expression of Na,K-ATPase-β₁ subunit increases uptake and sensitizes carcinoma cells to oxaliplatin

    • Ramakumar Tummala
    • Daniel Wolle
    • Lakshmi Pendyala

    Original Article Open access 26 March 2009 Pages: 1187 - 1194

    

17. Thymidylate synthetase allelic imbalance in clear cell renal carcinoma

    • Davide Colavito
    • Giuseppe Cartei
    • Alberta Leon

    Original Article 22 March 2009 Pages: 1195 - 1200

18. Thalidomide suppressed the growth of 4T1 cells into solid tumors in Balb/c mice in a combination therapy with the oncolytic fusogenic HSV-1 OncdSyn

    • Anna Israyelyan
    • Edward John Shannon
    • Konstantin G. Kousoulas

    Original Article 24 March 2009 Pages: 1201 - 1210

    

19. Experimental study of combination therapy with S-1 against pancreatic cancer

    • Jun Yoshizawa
    • Asako Takizawa
    • Yoshinori Yamada

    Original Article 01 April 2009 Pages: 1211 - 1219

    

20. Antiangiogenic and antiproliferative effects of substituted-1,3,4-oxadiazole derivatives is mediated by down regulation of VEGF and inhibition of translocation of HIF-1α in Ehrlich ascites tumor cells

    • Akhilesh Kumar
    • Saritha S. D’Souza
    • K. M. Lokanatha Rai

    Original Article 16 April 2009 Pages: 1221 - 1233

    

21. Pyrrolotetrazinones deazaanalogues of temozolomide induce apoptosis in Jurkat cell line: involvement of tubulin polymerization inhibition

    • Giampietro Viola
    • Laura Cecconet
    • Girolamo Cirrincione

    Original Article 11 April 2009 Pages: 1235 - 1251

    

22. Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma

    • Michele Reni
    • S. Cereda
    • E. Villa

    Original Article 21 April 2009 Pages: 1253 - 1259

    

23. Pharmacokinetics and metabolism of the putative cancer chemopreventive agent cyanidin-3-glucoside in mice

    • Timothy H. Marczylo
    • Darren Cooke
    • Andreas J. Gescher

    Original Article 11 April 2009 Pages: 1261 - 1268